To provide access to ALXN1840 treatment, an investigational medicinal product (IMP) that has
not yet been granted marketing authorization, to participants who complete Studies
ALXN1840-WD-205, WTX101-301, or ALXN1840-WD-302, or other studies with ALXN1840 who, in the
opinion of the Treating Physician, may benefit from continued treatment with ALXN1840, and
who meet the eligibility criteria described in this protocol.
How understandable was the trial content above?
Hard to understand
Easy to understand